Oppenheimer upgraded Dyne Therapeutics Inc (DYN) to Outperform from Perform on December 9, 2025. The stock is currently priced at $19.64.
This upgrade signals a more optimistic outlook on Dyne Therapeutics' prospects. It may reflect improved fundamentals, better-than-expected business performance, or increased confidence in the company's strategic direction.
Dyne Therapeutics, headquartered in Waltham, Massachusetts, focuses on developing innovative therapies for genetically driven muscle diseases. The company is leveraging its FORCE platform to create targeted therapeutics for conditions such as myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD).
Currently, Dyne has a market cap of $3.2 billion and an earnings per share (EPS) of -3.66. The company is preparing for upcoming earnings reports, with estimates of -$0.87 for EPS and $0 for revenue on July 27, 2026.
Analyst consensus remains positive, with 6 Strong Buy, 10 Buy, and 4 Hold ratings out of 20 total analysts, suggesting a general Buy sentiment. This upgrade adds to a series of recent analyst actions, including a maintained Overweight rating from Morgan Stanley and a maintained Buy rating from Chardan Capital.
Analyst ratings are informed by research and financial models, providing insights that reflect assumptions and estimates. Investors should consider these ratings alongside company fundamentals and market conditions before making decisions.